JP2016533358A - TCR−Nck相互作用の阻害剤としてのクロメン誘導体 - Google Patents
TCR−Nck相互作用の阻害剤としてのクロメン誘導体 Download PDFInfo
- Publication number
- JP2016533358A JP2016533358A JP2016522722A JP2016522722A JP2016533358A JP 2016533358 A JP2016533358 A JP 2016533358A JP 2016522722 A JP2016522722 A JP 2016522722A JP 2016522722 A JP2016522722 A JP 2016522722A JP 2016533358 A JP2016533358 A JP 2016533358A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- unsubstituted
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 14
- 150000008371 chromenes Chemical class 0.000 title abstract description 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 6
- 208000026278 immune system disease Diseases 0.000 claims abstract description 5
- 230000002062 proliferating effect Effects 0.000 claims abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- -1 2 - cyclopropyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- FKVDEQMQLFSIET-UHFFFAOYSA-N 6-(cyclopropylmethoxy)-N-ethyl-4-(4-fluorophenyl)-2H-chromene-3-carboxamide Chemical compound C1(CC1)COC=1C=C2C(=C(COC2=CC=1)C(=O)NCC)C1=CC=C(C=C1)F FKVDEQMQLFSIET-UHFFFAOYSA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- RQSCXXOQSAEPBM-UHFFFAOYSA-N 4-(4-fluorophenyl)-6-methoxy-2H-chromene-3-carboxylic acid Chemical compound FC1=CC=C(C=C1)C1=C(COC2=CC=C(C=C12)OC)C(=O)O RQSCXXOQSAEPBM-UHFFFAOYSA-N 0.000 claims description 2
- XVXGGRWSGCOEOM-UHFFFAOYSA-N 6-(cyclopropylmethoxy)-N-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-2H-chromene-3-carboxamide Chemical compound C1(CC1)COC=1C=C2C(=C(COC2=CC=1)C(=O)NCCN(C)C)C1=CC=C(C=C1)F XVXGGRWSGCOEOM-UHFFFAOYSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 150000000565 5-membered heterocyclic compounds Chemical class 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 5
- 210000004698 lymphocyte Anatomy 0.000 abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 0 *C(C1=C(c2ccc(*)cc2)c2cc(O*)ccc2OC1)=O Chemical compound *C(C1=C(c2ccc(*)cc2)c2cc(O*)ccc2OC1)=O 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100036943 Cytoplasmic protein NCK1 Human genes 0.000 description 1
- 108700037713 Cytoplasmic protein NCK1 Proteins 0.000 description 1
- 102100036952 Cytoplasmic protein NCK2 Human genes 0.000 description 1
- 108700037657 Cytoplasmic protein NCK2 Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108700002138 Nck Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091007411 Signalosomes Proteins 0.000 description 1
- 102000036646 Signalosomes Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 108091008091 TCR signalosome Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
R1は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6、置換もしくは未置換アリールまたは置換もしくは未置換ヘテロアリール、−COR5、−C(O)OR5、−C(O)NR5R6、−CNR5より選択され、
Xは−OHもしくは−NR2R3より選択され、
R2およびR3は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリール、置換もしくは未置換ヘテロアリール、−COR7、−C(O)OR7、−C(O)NR7R8、−CNR7、−OR7、−NR7R8、および−NR7C(O)R8より独立に選択されるか、
またはR2およびR3は、それらが結合する窒素原子とともに、置換もしくは未置換複素環を形成し、
R4はハロゲンであり、
R5、R6、R7およびR8は水素、C1〜C4アルキル、C3〜C6シクロアルキル、アリール、ヘテロアリール、およびハロゲンより独立に選択される。
R1は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリールまたは置換もしくは未置換ヘテロアリール、−COR5、−C(O)OR5、−C(O)NR5R6、−CNR5より選択され、
R2およびR3は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリール、置換もしくは未置換ヘテロアリール、−COR7、−C(O)OR7、−C(O)NR7R8、−CNR7、−OR7、−NR7R8、および−NR7C(O)R8より独立に選択されるか、
またはR2およびR3は、それらが結合する窒素原子とともに、置換もしくは未置換複素環を形成し、
R4はハロゲンであり、
R5、R6、R7およびR8は水素、C1〜C4アルキル、C3〜C6シクロアルキル、アリール、ヘテロアリール、およびハロゲンより独立に選択される。
− (4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− N−エチル−4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−カルボキサミド、
− (4−(4−フルオロフェニル)−6−メトキシ(methox)−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− N−(2−(ジメチルアミノ)エチル)−4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−カルボキサミド、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−エチル−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミド、および
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−エチル−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミド、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−(2−(ジメチルアミノ)エチル)−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミド。
a)式(II)の化合物を、式(III)の化合物および式(IV)の化合物と反応させるステップであって、
b)1つまたはそれ以上のステップにおいて、式(III)の化合物を式(I)の化合物に変換するステップ。
AX−105からAX−108に対する合成スキーム
EDCI(164mg、1.85mmol)およびHOBT(85mg、0.63mmol)を、酸2(194mg、0.57mmol)、ピロリジン(32mg、0.45mmol)およびDIPEA(220mg、1.71mmol)のTHF(10ml)溶液に加え、混合物全体をマイクロ波(900W)で4分間照射した。THFを最小体積に濃縮した。反応質量を氷冷水(20ml)で希釈し、EtOAc(3×25ml)で抽出した。混合有機抽出物をNa2SO4上で乾燥させて、ロータリーエバポレーター(rotavapor(登録商標))で濃縮することによって粗残留物をもたらし、これをFCC(SiO2、Hex−EtOAc混合物)で精製して、アミドAX−129(100mg、収率45%)をオフホワイト色の固体として生成した。1H NMR(DMSO−d6)δ 7.30−7.28(m,4H),6.88−6.80(m,1H),6.29(s,1H),4.77(s,2H),3.63(d,J=6.8Hz,2H),3.11(m,2H),3.03(s,2H),1.60−1.51(m,4H),1.10(m,1H),0.49(d,J=8.0Hz,2H),0.23(d,J=4.4Hz,2H).ES−MS[M+1]+:391.4。
AX−130:酸2(300mg、0.882mmol)から出発し、上記手順のピロリジンをエチルアミンに置き換えることによって、AX−130(130mg、収率76%)を薄黄色の粘着性の固体として調製した。1H NMR(DMSO−d6,400MHz):δ 7.63(t,J=4.8Hz,1H),7.27−7.25(m,4H),6.87−6.79(m,2H),6.17(s,2H),4.78(s,1H),3.61(d,J=5.1Hz,2H),2.9(m,2H),1.08(m,1H),0.69(t,J=7.2Hz,3H),0.48(d,J=8.0Hz,2H),0.22(d,J=4.4Hz,2H).ES−MS[M+1]+:368.1。
AX−131:酸2(200mg、0.588mmol)から出発し、上記手順のピロリジンをN−メチルピペラジンに置き換えることによって、AX−131(120mg、収率23%)を薄黄色の粘着性の固体として調製した。1H NMR(DMSO−d6,400MHz):δ 7.32(m,4H),6.91−6.84(m,2H),6.27(s,1H),4.81(s,2H),4.30(m,1H),3.89(m,1H),3.63(d,J=6.8Hz,2H),3.18(m,1H),2.75−2.56(m,4H),1.09(m,1H),0.49(d,J=8.0Hz,2H),0.23(d,J=4.4Hz,2H).ES−MS[M+1]+:423.1。
TBTU(514mg、1.6mmol)を、酸2(218mg、0.64mmol)のCH2Cl2(12ml)、DMF(2.5ml)およびDIEA(289mg、2.244mmol)の混合物の溶液にN2の下で加えた。室温にて撹拌した。1h後、4−アミノ−1−メチルピペリジン(221mg、1.923mmol)を加え、反応混合物全体を室温にて6h撹拌した。反応質量をCH2Cl2(70ml)で希釈し、水(2×25ml)で洗浄した。有機層をNa2SO4上で乾燥させて、ロータリーエバポレーター(rotavapor(登録商標))で濃縮することによって粗残留物をもたらし、これをFCC(SiO2:MeOH−CH2Cl2混合物)で精製して、アミドAX−132(100mg、収率39%)を薄黄色の油としてもたらした。1H NMR(DMSO−d6,400MHz):δ 7.58(m,1H),7.28−7.26(m,4H),6.16(s,1H),4.78(s,2H),3.61(d,J=6.4Hz,2H),3.45(m,1H),2.62(m,4H),2.21−2.00(m,6H),1.43(m,2H),1.40−1.00(m,6H),1.08(m,1H),0.48(d,J=7.6Hz,2H),0.21(m,2H).ES−MS[M+1]+:437.3。
TCRがTリンパ球の増殖を誘導する能力に対する化合物AX−105、AX−106、AX−107およびAX−108の効果を、健康なヒトドナーの血液から得た初代Tリンパ球(PBMC、末梢血単核細胞(peripheral blood mononuclear cells))において評価した。フィコール−パック・プラス(Ficoll−Paque Plus)密度勾配における静脈血の遠心分離によって、ボランティアのPBMCを単離した。精製した細胞(NWT;ナイロン・ウッドT細胞(Nylon Wood T cells))を、96ウェルプレート(0.5×105/ウェル)で200ulの完全培地にて3つ組で培養し、1uMおよび10uMの濃度の異なる化合物の存在下または不在下で、OKT3(10ug/ml)またはOKT3(1ug/ml)およびCD28によって刺激した。培養物を3日間インキュベートし、培養の最後の12hに0.5uCi[3H]TdR/ウェルを加えた後に分析した。液体シンチレーション測定によって、DNAに取り込まれた放射活性を定めた。細胞分裂の際に放射活性は娘細胞に取り込まれるため、これが細胞増殖の程度であると考えられる。テスト化合物の阻害能力を図1に示す。
糖尿病の発生を毎日モニタし、RIP−MOVAモデルで毎日、またはNODモデルで隔週取られている2回の連続した測定において250mg/dlを超える糖尿のレベル(leves)が検出されるときに、陽性と記録した。疾患の発生率および生存に対する処置の効果を、RIP−MOVAモデルにおいてそのまま膵島炎に対して評価した。パラフィンに浸漬し、ホルマリンで固定した切片H&Eの膵島炎の病理組織学的評価を、以下の分類系を用いた盲検によって評価した。ステージ0、浸潤なし;ステージ1、膵島周囲炎;ステージ2、浸潤>25%;ステージ3、浸潤>75%;およびステージ4、残りの膵島。第2相において、すでに糖尿病が発生したRIP−mOVAマウスに対する処置によって、化合物の治療効果を評価した。この第2相の際には、NODマウスモデルにおいて化合物をテストした。
Claims (26)
- 式(I)の化合物、
R1は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6、置換もしくは未置換アリールまたは置換もしくは未置換ヘテロアリール、−COR5、−C(O)OR5、−C(O)NR5R6、−CNR5より選択され、
Xは−OHもしくは−NR2R3より選択され、
R2およびR3は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリール、置換もしくは未置換ヘテロアリール、−COR7、−C(O)OR7、−C(O)NR7R8、−CNR7、−OR7、−NR7R8、および−NR7C(O)R8より独立に選択されるか、
またはR2およびR3は、それらが結合する窒素原子とともに、置換もしくは未置換複素環を形成し、
R4はハロゲンであり、
R5、R6、R7およびR8は水素、C1〜C4アルキル、C3〜C6シクロアルキル、アリール、ヘテロアリール、およびハロゲンより独立に選択される、化合物。 - 式(II)の化合物、
R1は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリールまたは置換もしくは未置換ヘテロアリール、−COR5、−C(O)OR5、−C(O)NR5R6、−CNR5より選択され、
R2およびR3は水素、置換もしくは未置換C1〜C6アルキル、置換もしくは未置換C3〜C6シクロアルキル、置換もしくは未置換アリール、置換もしくは未置換ヘテロアリール、−COR7、−C(O)OR7、−C(O)NR7R8、−CNR7、−OR7、−NR7R8、および−NR7C(O)R8より独立に選択されるか、
またはR2およびR3は、それらが結合する窒素原子とともに、置換もしくは未置換複素環を形成し、
R4はハロゲンであり、
R5、R6、R7およびR8は水素、C1〜C4アルキル、C3〜C6シクロアルキル、アリール、ヘテロアリール、およびハロゲンより独立に選択される、化合物。 - R1は置換または未置換C1〜C4アルキルである、請求項1または2に記載の化合物。
- R1は−CH3である、請求項3に記載の化合物。
- R1はC3〜C6シクロアルキルによって置換されたC1〜C4アルキルである、請求項3に記載の化合物。
- R1は−CH2−シクロプロピル基である、請求項5に記載の式(I)の化合物。
- R2はHである、請求項2から6のいずれか一項に記載の化合物。
- R3は置換または未置換C1〜C4アルキルである、請求項2から7のいずれか一項に記載の化合物。
- R3は−CH2−CH3基である、請求項8に記載の化合物。
- R3は−NR’R’’基によって置換されたC1〜C4アルキルであり、式中、R’およびR’’は、HまたはC1〜C4アルキルより独立に選択される、請求項8に記載の化合物。
- R3は−CH2−CH2−N(CH3)2基である、請求項10に記載の化合物。
- R2およびR3は、置換または未置換飽和5員複素環を形成する、請求項2から6のいずれか一項に記載の化合物。
- R2およびR3は、置換または未置換飽和6員複素環を形成する、請求項2から6のいずれか一項に記載の化合物。
- 前記飽和複素環は、その少なくとも1つの位置においてC1〜C4アルキルによって置換されている、請求項12または13に記載の化合物。
- 前記飽和6員複素環は、挿入された付加的な未置換N原子を含有するか、またはC1〜C4アルキルによって置換されている、請求項13に記載の化合物。
- R3は、未置換であるか、またはC1〜C4アルキルによって置換された付加的な挿入N原子を含有する飽和6員複素環である、請求項2から7のいずれか一項に記載の化合物。
- R4はフッ素である、請求項1から16のいずれか一項に記載の化合物。
- − (4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− N−エチル−4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−カルボキサミド、
− (4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− N−(2−(ジメチルアミノ)エチル)−4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−カルボキサミド、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−エチル−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミド、および
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(ピロリジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−エチル−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミド、
− (6−(シクロプロピルメトキシ)−4−(4−フルオロフェニル)−2H−クロメン−3−イル)(4−メチルピペラジン−1−イル)メタノン、
− 6−(シクロプロピルメトキシ)−N−(2−(ジメチルアミノ)エチル)−4−(4−フルオロフェニル)−2H−クロメン−3−カルボキサミドより選択される、請求項2に記載の式(I)の化合物。 - Xは−OHである、請求項1に記載の化合物。
- 4−(4−フルオロフェニル)−6−メトキシ−2H−クロメン−3−カルボン酸である、請求項19に記載の化合物。
- 薬物の製造のための、請求項1から20のいずれか一項に記載の式(I)の化合物の使用。
- Tリンパ球における前記TCR−Nck相互作用の介在する疾患または障害を処置するための薬物の製造のための、請求項1から20のいずれか一項に記載の式(I)の化合物の使用。
- Tリンパ球における前記TCR−Nck相互作用の介在する前記疾患または障害は、移植片拒絶、免疫性、自己免疫性および炎症性の疾患、神経変性疾患、血液病、ならびに増殖性疾患より選択される、請求項22に記載の使用。
- Tリンパ球における前記TCR−Nck相互作用の介在する前記疾患または障害は、移植片拒絶、関節リウマチ、乾癬性関節炎、乾癬、I型糖尿病、糖尿病による合併症、多発性硬化症、全身性エリテマトーデス、アトピー性皮膚炎、肥満細胞の介在するアレルギー反応、白血病、リンパ腫、ならびに白血病およびリンパ腫に関連する血栓閉塞性およびアレルギー性の合併症より選択される、請求項23に記載の使用。
- 請求項1から20のいずれか一項に記載の式(I)の化合物と、1つまたはそれ以上の薬学的に許容できる賦形剤とを含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201331543 | 2013-10-18 | ||
ES201331543A ES2534336B1 (es) | 2013-10-18 | 2013-10-18 | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
PCT/IB2014/002177 WO2015056086A1 (es) | 2013-10-18 | 2014-10-20 | Derivados de cromeno como inhibidores de interacción tcr-nck |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016533358A true JP2016533358A (ja) | 2016-10-27 |
JP6534995B2 JP6534995B2 (ja) | 2019-06-26 |
Family
ID=52002998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016522722A Active JP6534995B2 (ja) | 2013-10-18 | 2014-10-20 | TCR−Nck相互作用の阻害剤としてのクロメン誘導体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10106518B2 (ja) |
EP (1) | EP3059231B1 (ja) |
JP (1) | JP6534995B2 (ja) |
CN (1) | CN105636943B (ja) |
AU (1) | AU2014335860B2 (ja) |
CA (1) | CA2925863C (ja) |
ES (2) | ES2534336B1 (ja) |
RU (1) | RU2665709C2 (ja) |
WO (1) | WO2015056086A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514007A (ja) * | 2018-02-27 | 2021-06-03 | アルタックス バイオファーマ インコーポレイテッド | Tcr−nck相互作用の阻害剤としてのクロメン誘導体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2534318B1 (es) | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011526607A (ja) * | 2008-06-30 | 2011-10-13 | コンセホ スペリオール デ インベスティガシオネス シエンティフィカス(セエセイセ) | TCR−Nckの相互作用のブロックに基づく免疫抑制剤 |
JP2013537899A (ja) * | 2010-09-28 | 2013-10-07 | コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカス | クロメン誘導体 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0412939A3 (en) * | 1989-08-11 | 1991-09-04 | Ciba-Geigy Ag | Certain benzopyran and benzothiopyran derivatives |
PT1040106E (pt) * | 1997-12-19 | 2002-11-29 | Bayer Ag | Derivados de cromano substituidos com carboxi uteis como agonistas de adrenoreceptor beta 3 |
DE19858341A1 (de) * | 1998-12-17 | 2000-06-21 | Merck Patent Gmbh | Chromanderivate |
AU781986B2 (en) | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU2001278980A1 (en) | 2000-07-21 | 2002-02-05 | Chugai Seiyaku Kabushiki Kaisha | Coumarin derivatives useful as tnfalpha inhibitors |
WO2002066454A1 (en) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Chromene derivatives |
EP1392283A4 (en) | 2001-05-16 | 2004-10-20 | Cytovia Inc | COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS |
WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
AU2003241482A1 (en) * | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
WO2010009069A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Chromene modulators of chemokine receptor activity |
JP5578083B2 (ja) | 2008-12-05 | 2014-08-27 | アステラス製薬株式会社 | 2h−クロメン化合物及びその誘導体 |
ES2534318B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
-
2013
- 2013-10-18 ES ES201331543A patent/ES2534336B1/es not_active Expired - Fee Related
-
2014
- 2014-10-20 AU AU2014335860A patent/AU2014335860B2/en active Active
- 2014-10-20 CA CA2925863A patent/CA2925863C/en active Active
- 2014-10-20 ES ES14806053T patent/ES2869023T3/es active Active
- 2014-10-20 US US15/029,061 patent/US10106518B2/en active Active
- 2014-10-20 EP EP14806053.6A patent/EP3059231B1/en active Active
- 2014-10-20 JP JP2016522722A patent/JP6534995B2/ja active Active
- 2014-10-20 RU RU2016118038A patent/RU2665709C2/ru active
- 2014-10-20 CN CN201480057187.7A patent/CN105636943B/zh active Active
- 2014-10-20 WO PCT/IB2014/002177 patent/WO2015056086A1/es active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011526607A (ja) * | 2008-06-30 | 2011-10-13 | コンセホ スペリオール デ インベスティガシオネス シエンティフィカス(セエセイセ) | TCR−Nckの相互作用のブロックに基づく免疫抑制剤 |
JP2013537899A (ja) * | 2010-09-28 | 2013-10-07 | コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカス | クロメン誘導体 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514007A (ja) * | 2018-02-27 | 2021-06-03 | アルタックス バイオファーマ インコーポレイテッド | Tcr−nck相互作用の阻害剤としてのクロメン誘導体 |
JP7317032B2 (ja) | 2018-02-27 | 2023-07-28 | アルタックス バイオファーマ インコーポレイテッド | Tcr-nck相互作用の阻害剤としてのクロメン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
RU2016118038A (ru) | 2017-11-23 |
EP3059231B1 (en) | 2021-02-17 |
ES2534336B1 (es) | 2016-01-28 |
RU2665709C2 (ru) | 2018-09-04 |
CA2925863C (en) | 2018-12-04 |
CN105636943A (zh) | 2016-06-01 |
AU2014335860B2 (en) | 2018-06-28 |
WO2015056086A1 (es) | 2015-04-23 |
EP3059231A1 (en) | 2016-08-24 |
ES2869023T3 (es) | 2021-10-22 |
AU2014335860A1 (en) | 2016-05-05 |
JP6534995B2 (ja) | 2019-06-26 |
US10106518B2 (en) | 2018-10-23 |
CN105636943B (zh) | 2019-01-22 |
CA2925863A1 (en) | 2015-04-23 |
ES2534336A1 (es) | 2015-04-21 |
US20160251330A1 (en) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI299040B (en) | Pyrimidine derivatives | |
NL2000336C2 (nl) | Spirocyclische derivaten. | |
RU2765718C1 (ru) | Замещенное производное дигидропирролопиразола | |
MX2015002807A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble. | |
TW201002708A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
JP2022070895A (ja) | ニューロキニン-1受容体アンタゴニストとしての化合物およびその使用 | |
US11634407B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
BR112021014514A2 (pt) | Inibidores de via de resposta integrada ao estresse | |
BR112020023115A2 (pt) | inibidores da via integrada de resposta a tensão | |
JP5793182B2 (ja) | Ccr1受容体アンタゴニストとしてのアザインダゾールアミド化合物 | |
KR101800919B1 (ko) | 크로먼 유도체들 | |
JP6534995B2 (ja) | TCR−Nck相互作用の阻害剤としてのクロメン誘導体 | |
JP6505095B2 (ja) | Tcr−nck相互作用の阻害剤としての、アルコキシドによって置換されたクロメン誘導体 | |
AU2017209023A1 (en) | 2-oxindole compounds | |
KR20240068057A (ko) | 치환된 1,4-다이하이드로-1,6-나프티리딘 아미드 및 이의 용도 | |
JP2019523248A (ja) | 心臓代謝性疾患の処置に有用なhriアクチベーター | |
BR112017026994B1 (pt) | Composto, e, composição farmacêutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180417 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6534995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |